Oncogene c-Myc is frequently amplified and activated in human cancers. Deregulation of c-Myc protein has been shown to occur in 30% of all human cancers, especially in hematopoietic malignancies. As a transcription factor, c-Myc has been shown to regulate up to 15% of all human genome genes, controlling diverse cellular activities including cell cycle, ribosome biogenesis, protein synthesis, metabolism, apoptosis and angiogenesis. In this report, we provide evidence that the RNA helicase DHX33 is a critical downstream target of c-Myc. Myc binds to DHX33 upstream promoter region and stimulates its transcription. Elevated DHX33 protein is pivotal for c-Myc to drive tumor formation. Knockdown of DHX33 to basal levels in c-Myc overexpressing cells significantly reduced cell proliferation, cell migration and anchorage-independent cell growth in vitro and in vivo. Additionally, we found that DHX33 promotes MMP9, MMP14 and urokinase-type plasminogen activator (PLAU) transcription by directly binding to their promoters, thus promoting cancer cell migration. DHX33 protein was overexpressed in a certain subset of human non-Hodgkin's lymphoma tissues. Finally, knockdown of DHX33 significantly inhibits the development of Myc-induced acute myeloid leukemia. Overall, our results implicate the important role for DHX33 in Myc-induced cancer and point toward its potential therapeutic value in Myc driven cancers.
Introduction
The proto-oncogene Myc encodes a basic helix-loop-helix leucine zipper transcription factor that forms dimers with its binding partner Max to activate various target genes involved in cell cycle progression, metabolism, angiogenesis, differentiation and apoptosis (1) . The transcription factor Myc is regarded as a master regulator of protein synthesis and ribosome biogenesis (2) . Frequent activating mutations, gene amplification and chromosome translocation of Myc have been detected in human cancers including hematologic malignance, prostate, breast cancer, colon cancer and myeloma (3) (4) (5) (6) (7) . Inhibition of c-Myc through various means has been shown to effectively inhibit Ras, PI3K, BRAF driven cancer (8) (9) (10) . However, direct pharmacological targeting of c-Myc has been proven to be difficult.
DHX33 belongs to a family of DEAD/DEAH box RNA helicases that are characterized by a conserved DEAD/DEAH peptide motif and seven other motifs in their primary amino acid sequences (11) . RNA helicases can couple ATP hydrolysis with conformational change of nucleic acid (12) . In eukaryotic cells, genome DNA decodes into various RNA species, they carry the information to encode proteins, to play catalytic activities and to regulate gene expression transcriptionally or post-transcriptionally. RNA/DNA structure can be modified by DEAD/DEAH box proteins. Through influencing the structure and activity of RNA/DNA molecules, DEAD/DEAH box proteins participate in many cellular activities, including ribosome biogenesis, miRNA biogenesis, transcription, splicing, translation and mRNA decay (13) . Deregulated expression of DEAD/DEAH box protein has been frequently observed in human cancers. Evidence shows that cancer cells could hijack these proteins to facilitate cancer cell proliferation (14, 15) .
We previously identified DHX33 to be an important player in ribosome RNA synthesis and protein translation (16, 17) , we further discovered that DHX33 resides downstream of Ras to promote cancer development (18) . DHX33 was also found to be important in innate immunity, as it can sense dsRNA from pathogens (19) . A recent report shows that DHX33 protein is upregulated in liver cancer (20) , however, not much evidence has been shown to correlate DHX33 with the development of human cancers.
In this study, we explored the regulation of DHX33 by c-Myc and found that c-Myc/Max heterodimer binds to DHX33 proximal promoter and regulates its transcription directly. The upregulation of DHX33 gene transcription is pivotal to promote Myc driven cancer initiation and development. Finally, we discovered that inducible knockdown of DHX33 severely inhibited the development of Myc-induced acute myeloid leukemia after bone marrow cell transplantation.
Materials and Methods

Cell culture
NIH3T3 cells were maintained in DMEM medium containing 10% fetal bovine serum (FBS), 2mM L-Glutamine and streptomycin and penicillin. H1299, K562 and Daudi cells were maintained in the ATCC-formulated RPMI-1640 supplemented with fetal bovine serum to a final concentration of 10%, 2 mM L-Glutamine, streptomycin and penicillin. HEK293T cells were maintained in DMEM medium containing 10% FBS and streptomycin/penicillin. All cell lines were purchased from ATCC and authenticated before usage.
Plasmids
Full-length human c-Myc cDNA (NM_001031725.4) was cloned from human primary cell cDNA library. Primers were designed to clone the open reading frame (ORF) of c-Myc into pLVX-IRES-hygromycin at XhoI/ BamHI sites. pBABE-Myc-ER and pMSCV-Myc-IRES-GFP were purchased from Addgene. pMSCV-IRES-GFP was a kind gift from Dr. Jason D.Weber lab (Washington University in St. Louis). pGL3-control plasmid was purchased from Promega. Human DHX33 promoter sequence was cloned into pGL3-control vector at the NheI/XhoI site. Site-directed mutagenesis was performed at the three E-box sites on this promoter by Stratagene site-directed mutagenesis kit. pTET-puro was purchased from Addgene. To clone inducible DHX33 knockdown plasmid, the following shRNA targeting DHX33 was used: 5′-GCTATCGCAAAGTGATCATTT-3′. A scrambled shRNA sequence was also cloned into pLKO.1 and pTET-puro vector. All plasmids were sequenced to make sure they are correct.
Lentivirus/Retrovirus production
The targeting sequences of shRNAs for human DHX33 are as follows: (5′-3′): sh-hDHX33-1: CTCGGGAAACTTCCTCTGAAA; sh-hDHX33-2: GCTATCGCAAAGTGATCATTT; sh-hDHX33-3: CATTTCCTTTAGAACCCAAAT. The targeting sequences of shRNAs for mouse DHX33 are as follows: (5′-3′): sh-mDHX33-1: CCTAGCAATGAAAGTCCCAAA; sh-mDHX33-2: CTAGCAATGAAAGTCCCAAAT. The targeting sequences of shRNAs for human c-Myc are as follows: (5′-3′): sh-c-Myc-1: CAGTTGAAACACAAA CTTGAA; sh-c-Myc-2: CCTGAGACAGATCAGCAACAA. The targeting sequence of inducible shRNA for human DHX33 is as follow: 5′-GCTATCGC AAAGTGATCATTT-3′, standard protocol was followed to clone this shRNA sequence into pLKO-Tet-ON vector. To produce knockdown virus, 293T cells were transfected by pLKO.1-shRNA, pCMV-VSV-G, pHR8.2ΔR by Lipofectamine 2000 (Life Technologies) for virus packaging. To produce inducible knockdown virus, 293T cells were transfected by pLKO-Tet-ONshRNA, pLP1, pLP2, pLP/VSVG by Lipofectamine 3000 (Life Technologies) for virus packaging. To generate lentivirus overexpressing c-Myc, 293T cells were transfected by pLVX-c-Myc-IRES-hygro, pCMV-VSV-G, pHR8.2ΔR. To produce retrovirus encoding Myc-ER, 293T cells were transfected by pBABE-Myc-ER, pUMVC, pVSV-G. To produce MSVC retrovirus, pMSVCMyc-IRES-GFP or the empty vector and ψ 2 were co-transfected into 293T cells. For viruses, the culture supernatants were harvested 24 h and 48 h after transfection and then centrifuged at 2000 rpm for 5 min.
Immunoblotting
Whole cell lysates were prepared by incubation with whole cell lysis buffer that included 0.5% NP40 and 1% SDS supplemented with HALT protease and phosphatase inhibitors (Sigma). Lysates were cleared by centrifugation and protein concentration was tested by DC assay (BioRad). Lysates were boiled with SDS sample buffer, separated by SDS-PAGE and transferred to polyvinylidene difluoride membrane (Millipore). Membranes were blocked in 5% nonfat dry milk TBS-T [10 mmol/L TrisHCl (pH 7.4), 150 mmol/L NaCl, 0.1% Tween 20] buffer and incubated in primary antibodies diluted in blocking buffer at 4°C overnight. Blots were washed with TBS-T buffer and incubated with horseradish peroxidaseconjugated secondary antibodies (1:10 000; GE Healthcare) in blocking buffer at room temperature. Immune complexes were visualized with an Enhanced Chemiluminescence kit (GE Healthcare). Primary antibodies for immunodetection were sourced as follows: anti-tubulin (goat, Santa Cruz, sc-7396), anti-DHX33 (Santa Cruz, sc-137424), anti-GAPDH (Bethyl), anti-cMyc (Santa Cruz, sc-764), anti-MMP9 (Santa Cruz, sc-10737).
BrdU for cell proliferation assay
Cells were previously seeded onto coverslips and at least incubated overnight after plating. BrdU was added at a final concentration of 10 μM, and incubated for 18 h. Cells were then fixed at appropriate fixation buffer (2% PFA or 10% Methonol/10% formalin in PBS) for 15 min at room temperature. Cells were then permeabilized with 0.3% Triton X-100 in PBS for 5 min. After washing with PBS once, cells were then treated with 1.5N HCl at room temperature for 10 min, then blocked with 10%FBS/PBS for 1 h at room temperature. A mouse monoclonal BrdU antibody (1:100) was applied onto the cells and then incubated for 1 h at room temperature or overnight at 4 o C. Goat-anti-mouse-Rhodamine (1:200) was added into the fixed cells and incubated for half an hour at room temperature in the dark. The coverslips were washed for 5 times with PBS and then mounted with DAPI. Cells were then ready to be visualized under fluorescence microscope.
Transwell migration assay
Transwell migration assay plates were purchased from Corning, standard protocol as followed according to manufacturer's protocol.
Soft agar assay
1.0 × 10 4 cells were mixed in 4.0 mL 0.3% agar/DMEM/10% FBS as the top agar and plated into 60mm plates with 4.0 mL 0.6% agar/DMEM/10% FBS as the base agar. Plates were incubated at 37°C, checked every 3 days, and fed with 2.0 ml 0.3% agar/ DMEM/10% FBS every week. Colonies were photographed and counted 2-3 weeks later.
Immunohistochemistry
Human tumor tissue microarrays were purchased from US Biomax. This tissue microarray contains 38 cases of non-Hodgkins lymphoma tissue. A Rabbit polyclonal anti-human DHX33 antibody (Santa Cruz) was used at 1:25. Tissue slides were deparaffinized in xylene and rehydrated in a series of graded alcohols and the antigen was retrieved in Tris buffer (pH 9.0) using a steamer. The sections were then treated with 1% hydrogen peroxide in methanol for 30 min to exhaust endogenous peroxidase activity. After pre-incubation in 10% normal fetal bovine serum for one hour to prevent nonspecific staining, the samples were incubated with primary antibody at room temperature for 2 h. Standard protocol was then followed based on DAKO envision kit using polymer to amplify signals. Both immunoreactive intensity and percentage of stained cells in different areas of the same slide were analyzed according to criteria described (21) . DHX33 expression was designated as 0 = no staining; 1 = weak; 2 = moderate; and 3 = strong. Additional points were scored as one, two, or three when the percentage of positive cells was less than 25%, 25% to 50%, or greater than 50%, respectively.
Quantitative PCR
The primers were all designed by qPCR design tool from IDTDNA (www. idtdna.com) and purchased from Life Technologies. Total RNA was extracted by use of a NucleoSpin II (Clontech) RNA isolation kit and was reverse transcribed into cDNA by a SuperScript III first-strand synthesis kit (Invitrogen). PCRs were performed with a
Step one plus thermal cycler. SYBR green mix from Bio-Rad was used for all quantitative real-time PCR (qRT-PCR) analyses. Transcript quantification was calculated based on the ΔΔ CT value after normalization to GAPDH values. Melt curve analysis confirmed that single products were amplified.
Chromatin Immunoprecipitation
After cells were trypsinized and resuspended into complete media, formaldehyde was added to a final concentration of 1% to crosslink DNA and its interacting proteins; this is performed at room temperature for 10 min with a shaker. To stop cross-linking, 1.25 M l-glycine was added to a final concentration of 0.125 M; the mixture was shaken at room temperature for 5 min. After washing with 1× PBS, cells were then resuspended in lysis buffer containing 1% SDS, 10 mM EDTA, and 50 mM Tris (pH 8.1) with protease and phosphatase inhibitors. To shear chromatin, cell lysates were sonicated extensively, centrifuged to pellet debris, and then diluted in buffer containing 0.5% NP-40, 50 mM Tris (pH 7.5) and 150 mM NaCl at a 1:5 ratio. Cell lysates were pre-cleared by incubation with 2.5 μg of sheared salmon sperm DNA and 50 μl protein A/G beads for 30 min at 4°C. Following incubation with 5 μg of antibody overnight at 4°C, 2.5 μg sheared salmon sperm DNA and 50 μl of protein A/G beads were added and then further incubated for 1 h. The beads were then washed twice in radioimmunoprecipitation assay (RIPA) buffer, twice in RIPA buffer containing 500 mM NaCl, and once with buffer containing 0.5% NP-40, 50 mM Tris (pH 7.5), and 150 mM NaCl. The beads were then extracted three times with a solution containing 1% SDS and 0.1 M NaHCO 3 . To reverse the cross-linking, 6 M NaCl was added into the pooled extraction samples to a final concentration of 0.3 M, and samples were heated at 65°C for 5 h. DNA fragments were extracted by the use of a Qiagen QuickSpin column and eluted. Quantitative PCR (qPCR) was performed with these purified DNA samples. The following primers were used for analysis of gene promoters: hMMP9 promoter Forward primer: 5′-TTTTCCCCCATATCCTGCCC-3′ hMMP9 promoter Reverse primer: 5′-CAAACTGCAGAGCTTGTGGG-3′ hMMP14 promoter Forward primer: 5′-CATCTGTCTCCCTTTCTCACG-3′ hMMP14 promoter Reverse primer: 5′-GTTTAGTTCCACCTCTACAC TGA-3′ hPLAU promoter Forward primer: 5′-GAAGTGCTAGGTGAAGAGGTG-3′ hPLAU promoter Reverse primer: 5′-TGTCATGCTGATTGCTGAGAG-3′ mDHX33 promoter 1 Forward primer: 5′-ACGATAGCTGTGTGGTTCCC-3′ mDHX33 promoter 1 Reverse primer: 5′-GGCCATACCGGATTCCACAA-3′ mDHX33 promoter 2 Forward primer: 5′-CCCGAGTAACAACAGGGGAC-3′ mDHX33 promoter 2 Reverse primer: 5′-TCACGGGGGACCCAGATATT-3′ mDHX33 promoter 3 Forward primer: 5′-CAGGCACAGAGTGAATGGGT-3′ mDHX33 promoter 3 Reverse primer: 5′-GGCCATACCGGATTCCACAA-3′ mDHX33 promoter 4 Forward primer: 5′-GGCACAGAGTGAATGGGTGG-3′ mDHX33 promoter 4 Reverse primer: 5′-ACTGGGATTTGGGGGTGTTT-3′
Bioluminescence imaging
Cells were plated in a 6-well tissue dish and co-transfected with pGL3-control-human DHX33 promoter-F-luc and pGL3-R-luc. Twenty-four hours later, the cells were replated in 96-well plates, D-luciferin and coelenterazine were added, and the plate was imaged with an IVIS-100 instrument. These cells were also harvested for total RNA extraction and analyzed by RT-PCR for determination of firefly luciferase (F-luc) transcript levels. To analyze firefly luciferase mRNA levels, the following other primers were used: firefly luciferase forward primer 5′-CCCTGGTTCCTGGAACAATT-3′ and firefly luciferase reverse primer 5′-GCAACCCCTTTTTGGAAACG-3′. Transfected cells were then analyzed for F-luc DNA levels. 
Bone marrow transplantation
Bone marrow transplantation (BMT) was essentially performed according to previous report (22) . On day 8 of each BMT procedure, 6 to 8 week-old BALB/c mice were pretreated with 150 mg/kg of 5-fluorouracil administrated by intraperitoneal injection. On day 2, bone marrow was harvested from these donor mice and red blood cells were lysed by incubation for 5 min on ice with an ammonium chloride lysis solution (150 mM NH 4 Cl, 10mM KHCO 3 , 0.1 mM EDTA (pH 7.4). The mononuclear marrow cells were then resuspended in RPMI medium containing 20% FBS, 6 ng/mL recombinant mouse IL-3 (PeproTech), 100 ng/mL recombinant mouse stem cell factor (PeproTech), and 10 ng/ml recombinant mouse IL-6 (PeproTech). The cells were then plated onto a culture plate pretreated with fibronectin. The next day, cells were infected by retrovirus encoding MSCV-Myc-IRES-GFP or MSCV-GFP. Two days later, cells were then further infected by lentivirus encoding inducible shRNA. A total of 5 × 10 5 cells were injected by tail vein into BALB/c NUDE mice. Animals were monitored 2 times per week for the development of disease by inspection and palpation of the spleen and femoral lymph nodes. Mice with disease evidence by abnormal white blood cell counts were sacrificed by cervical dislocation. Bone marrow cells were isolated by flushing femurs and tibias with PBS. Single-cell suspensions were prepared by passing spleen and lymph node tumor tissue through nylon mesh wetted with PBS. The cells were further analyzed by flow cytometry for GFP production and gated accordingly.
Results
c-Myc upregulates DHX33 transcription
To investigate whether DHX33 could be a potential downstream target of c-Myc, we transduced NIH3T3 cells with retrovirus that encodes Myc-Estrogen Receptor (Myc-ER) fusion protein. After the addition of 4-hydroxytamoxifen, Myc-ER would translocate into the nucleus, where Myc acts as a transcription factor to influence target gene expression. To verify that Myc-ER can upregulate target gene transcription in this experimental system, we analyzed the mRNA levels of cyclin D1 and 47S pre-rRNA, which have previously been shown to be regulated by c-Myc (23, 24) . As shown in Figure 1A , DHX33 mRNA was significantly upregulated after the treatment with 4-hydroxytamoxifen for 3 h. Likewise, the protein levels of DHX33 were also elevated by 4-hydroxytamoxifen treatment ( Figure 1B ). Cyclin D1 mRNA was elevated significantly while the increase of pre-rRNA appears to be delayed after DHX33 accumulation, implicating that rRNA transcription could be indirectly activated by Myc through DHX33. To confirm that levels of DHX33 mRNA and protein can be induced by Myc, we further used lentivirus encoding Myc to transduce NIH3T3 directly. As shown in Figure 1C and D, we found that both the mRNA levels and protein levels of DHX33 can be significantly elevated by Myc protein overexpression. Myc regulates target gene expression through directly binding to the conserved E-box in the promoters. The conventional E-box sequence is CACGTG where c-Myc binds tightly; Myc can also bind to nonconventional E-box as shown in Figure 1E under proper conditions (25) . To check whether DHX33 promoter contains such potential c-Myc binding sites, we search for these sequences in the DHX33 gene promoter. As shown in Figure 1F , we found four putative Myc binding boxes in the proximal promoter of DHX33.
c-Myc binds to the promoter element of DHX33
To analyze whether c-Myc can bind to the promoter of DHX33, we firstly performed chromatin immunoprecipitation analysis. NIH3T3 cells were cross-linked and immunoprecipitated with anti-Myc antibody after transduction with lenvirus encoding Myc protein. We designed four different sets of primers to encompass different region of DHX33 promoter ( Figure 2A ). As shown in Figure 2B , from all four sets of primers, we found that Myc binds to the promoter region of DHX33 as compared to IgG as a negative control. We further performed ChIP analysis with 3T3 cells that were transduced with Myc-ER retrovirus. After inducing the nuclear location of Myc by the addition of 4-hydroxytamoxifen, we analyzed the binding of Myc with DHX33 promoter. We found that after tamoxifen treatment, the binding between Myc and the promoter of DHX33 increased, while in the control group without tamoxifen treatment, the interaction between c-Myc and DHX33 promoter remained almost the same between anti-Myc and IgG control. To further unravel whether the interaction between DHX33 promoter and Myc is direct or not, we cloned the promoter from genome and performed electronic mobility shift assay with recombinant Myc/Max protein dimer. As shown in Figure 2C , the incubation of Myc/Max protein markedly GAPDH was used as an internal control. *P < 0.05, n = 3. (D) Above-mentioned cells were harvested for protein analysis by western blots with the indicated antibodies.
Quantification for DHX33 protein levels is shown. (E) Conventional and unconventional E-box that can bind to c-Myc transcription factor. (F) Bioinformatics analysis
showed that four potential Myc binding sites were located in human DHX33 promoter region.
shifted the DHX33 promoter bands up, while the competitive unlabeled DHX33 promoter restored them to the previous band position. Mutation of the E binding box in the promoter decreased the binding between DHX33 promoter and Myc/Max. These results are consistent with the hypothesis that Myc is able to directly bind to the DHX33 promoter. We further verify these results by the application of Firefly luciferase assay, for which we cloned the wild type or E-box mutated DHX33 promoter into the pGL3 control plasmids. The cloning diagram is shown in Figure 2D . As shown in Figure 2E , we found that the activity of DHX33 promoter was decreased significantly in c-Myc knockdown cells. Similarly, mutations of E-box in the DHX33 promoter sequence decreased the luciferase activity while wild type DHX33 promoter enhanced luciferase activity ( Figure 2F ). Our results indicated that DHX33 promoter can be bound by c-Myc directly and this increased the transcriptional activation of DHX33.
DHX33 expression correlates with Myc protein expression and is pivotal for cancer cell anchorageindependent cell growth
To study whether Myc could upregulate DHX33 in established cancer cell lines, we chose leukemia cell lines, K562 and Daudi, which have previously been found to contain higher level of c-Myc protein. We knocked down c-Myc gene expression for leukemia cells and then analyzed the mRNA and protein levels of DHX33. As shown in Figure 3A and D, knockdown of c-Myc in K562 and Daudi greatly decreased the protein and mRNA levels of DHX33 ( Figure 3B and E). Importantly, we found that knockdown of DHX33 caused significant reduction for cancer cell growth by the soft agar analysis ( Figure 3C and F). DHX33 was found to promote 47S pre-rRNA synthesis, to evaluate whether loss of DHX33 would influence Myc dependent rRNA biogenesis; we knocked down DHX33 gene expression in Mychigh Daudi cells. As shown in Figure 3G , we found that DHX33 deficiency did not cause reduction of 47S pre-rRNA levels, possibly due to inhibition of rRNA processing after knockdown of DHX33.
Induction of DHX33 by Myc is important to drive cell proliferation and cell migration
To investigate whether DHX33 plays an important role in Myc-induced cellular transformation, we performed several experiments on Myc overexpressing cells after DHX33 was knocked down. As shown in Figure 4A , the protein level of DHX33 was markedly reduced by transduction of lentivirus encoding shRNA in c-Myc overexpressing cells. We found that the phenotype of these cells changed markedly. Firstly of all, cell proliferation rate as analyzed by BrdU incorporation was greatly decreased in NIH3T3 cells after knockdown of DHX33 ( Figure 4B and C) . Additionally, we found that cell migration as analyzed by Transwell assay was also greatly inhibited due to DHX33 deficiency ( Figure 4D and E). It is widely known that Myc oncogene can transform fibroblast cells into cancerous cells. Therefore, lastly, we analyzed Myc transforming activity by soft agar assay. When DHX33 protein level was decreased to basal level in Myc overexpressing NIH3T3 fibroblasts, we found that these cells lost their tumorigenecity as demonstrated by the few and smaller colonies in soft agar plates ( Figure 4F ). The quantitation for soft agar analysis is shown in Figure 4G .
DHX33 promotes cell migration through transcriptionally controlling MMP9, MMP14 and PLAU
Previously we have found several functions for DHX33 to promote cell proliferation; these functions include protein translation, ribosome biogenesis (16, 17) . However, no function for DHX33 has yet been linked to cell migration. To further study the molecular mechanisms for DHX33 to promote cancer cell migration, we focused our attention on several cell migration related genes, which have been found to be significant downregulated after knockdown of DHX33 through RNA sequencing (26) . As shown in Figure 5A , we found that the mRNA levels of MMP9, MMP14 and PLAU were significantly downregulated, while those of Slug, Vimentin and Twist2 were not. Through analysis of DHX33 inducible knockdown cell samples, we found that the transcription of MMP9, MMP14 and PLAU mRNA were markedly decreased too ( Figure 5B ). We further found the reduction of protein levels for MMP9 in DHX33 deficient cells ( Figure 5C ). To unravel the molecular mechanism, we performed ChIP analysis and found that DHX33 can bind to the promoter region of MMP9, MMP14 and PLAU, while c-Myc could not ( Figure 5D ). Because these genes play important roles in promoting cancer cell migration and are frequently deregulated (27) , we predicted that the reduction of these proteins would cause decreased cancer cell invasion. As shown in Figure 5E , the reduction of DHX33 caused significant deceased invasion ability for lung cancer cells.
DHX33 is highly expressed in a subset of human lymphomas and lung cancers with c-Myc dysregulation
Myc has been regarded as the third most commonly amplified oncogene in human cancers, deregulation for c-Myc protein has been regarded as a causal factor in leukemia and lymphoma (28) . Myc has also been shown to be important in various oncogene induced cancer formation such as Ras, BRAF, Notch (8, (29) (30) (31) . To analyze whether the protein levels of DHX33 could be increased due to Myc activation in cancer tissues, we performed immunohistochemistry staining for DHX33 in a set of human non-Hodgkin's lymphoma tissues. As shown in Figure 6A , we found that DHX33 protein level is higher in many lymphoma tissues. Furthermore, we searched the TCGA database and found that the mRNA levels of DHX33 are higher than normal lymph node tissues ( Figure 6B ). These results indicate that DHX33 is a highly expressed protein in human cancer tissues. c-Myc has been shown to be highly expressed in almost 10% of human non-small cell lung cancers. To study whether c-Myc and DHX33 protein expression might correlate, we performed immunohistochemistry staining to detect the protein levels of c-Myc and DHX33 in a human non-small cell lung cancer tissue array. As shown in Figure 6C , we found 6 out of 10 human lung cancers expressed DHX33 and Myc simultaneously.
DHX33 is critical in Myc driven cancer
To explore the role of DHX33 in Myc driven cancers, we firstly analyzed the formation of tumor in immunocompromised mice by Myc overexpressing NIH3T3 cells. As shown in Figure 7A and B, after knockdown of DHX33, the efficiency for solid tumor formation was greatly decreased in immunodeficient mice. Previously c-Myc has been reported to be able to efficiently induce acute myeloid leukemia in bone marrow cells (32, 33) . To mimic myeloid leukemia formation in vivo, we isolated bone marrow cells and infected them with retrovirus encoding MSCV-Myc-IRES-GFP. These cells were then further infected with lentivirus encoding a tetracycline-inducible shRNA to knockdown DHX33 specifically, with shSCR as a control. After injecting these cells into immunodeficient mice, we then monitored the development of acute myeloid leukemia. After we detected the appearance of leukemia by periphery blood analysis, the DHX33-shRNA mice group was then randomly divided into two sub-groups. One sub-group is for control that we fed with 1% sucrose, the other sub-group was fed with doxycycline in 1% sucrose. As shown in Figure 7C and D, we found significant reduction of GFP expressing myeloid leukemia cells for DHX33-shRNA mice group that were treated with doxycycline, while in the two control groups, marked increase of GFP positive myeloid leukemia cells were detected in the periphery blood. protein. The development of Myc driven solid tumor and acute myeloid leukemia were both severely debilitated after knockdown of DHX33. We further discovered that DHX33 transcriptionally regulates MMP9, MMP14 and PLAU gene expression, and mediates Myc-promoted cancer cell migration/invasion. c-Myc is a central player during normal cell proliferation, it is essential for cell metabolism, cell cycle progression and ribosome biogenesis (1, 28) . Due to its important role in controlling cell growth, c-Myc is succumbed to multiple levels of regulation transcriptionally or post-transcriptionally (34) . Deregulation of c-Myc has been frequently detected in almost all human cancers (34) . Studies with mouse cancer models show that c-Myc is essential for RAS, BRAF and Notch induced cancer development (35) . Recent evidence suggests that reversible Myc inhibition with omomyc, a Myc dominant negative form which binds to Max but is unable to transactivate downstream genes, caused Ras induced cancer to be eradicated (8) . Myc overexpressing cells are metabolically addicted, targeting metabolic enzymes might be a way to treat Myc driven cancers. Despite these efforts, no effective drug has been successfully developed to target c-Myc in the clinic.
DHX33 was identified by our research group to be a critical regulator in cell proliferation and cell growth. DHX33 was found to be involved in protein translation, ribosome biogenesis and cell cycle progression (16) (17) (18) 24) . As stated previously, c-Myc promotes protein translation and ribosome biogenesis; this is at least partially mediated by DHX33, as knockdown of DHX33 in Myc-high cells completely abolished cell proliferation. We found that DHX33 actively and selectively regulates the transcription of genes involved in cancer cell invasion. Transcriptional regulation of MMP9, MMP14 and PLAU by DHX33 may partially explain the roles of DHX33 in Myc driven cancers. Post-transcriptional regulation such as selective protein translation by DHX33 may play important parts for Myc driven cancers, too. This is worthwhile to be further investigated.
What has been found about DHX33 protein in Myc driven cancers has important clinical implication, as we have found that the enzymatic activity of DHX33 is required for cells to promote ribosome biogenesis and protein translation. These data support the development of DHX33 specific inhibitors for treating Myc driven cancers. 
